Implementing high-dose rate surface mould brachytherapy for carcinoma of eyelid: a practical approach and weekly review

Surface mould brachytherapy is a conformal radiotherapy technique that can deliver high dose to the target while sparing nearby normal structures, Here, we aim to describe the procedurals details for high-dose rate (HDR) surface mould brachytherapy in sebaceous carcinoma of eyelid in a 54-year old l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiation oncology journal 2024, 42(2), , pp.154-159
Hauptverfasser: Patro, Kanhu Charan, Avinash, Ajitesh, Banidutta, Arya, Kundu, Chitta Ranjan, Bhattacharya, Partha Sarathi, Pilaka, Venkata Krishna Reddy, Muvvala, Mrutyunjayarao, Kumar, Ayyalasomayajula Anil, Aketi, Srinu, Karthikeyan, Keerthiga, Madasu, Bhargava Krishna, Vincent, Dona Treesa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Surface mould brachytherapy is a conformal radiotherapy technique that can deliver high dose to the target while sparing nearby normal structures, Here, we aim to describe the procedurals details for high-dose rate (HDR) surface mould brachytherapy in sebaceous carcinoma of eyelid in a 54-year old lady. She was hesitant for surgery and any form of invasive intervention like interstitial brachytherapy. So, she was treated with surface mould HDR brachytherapy to a total dose of 52 Gy in 13 fractions at a dose of 4 Gy per fraction delivered twice daily using Iridium-192 isotope with no acute side effects. She was evaluated on a weekly basis for any radiation side effects and now she is disease-free for 6 months post-treatment with only mild dry eye. A detailed step-by-step procedure of surface mould technique, simulation procedure, dose prescription, planning, plan evaluation and treatment has been described in this paper. Surface mould HDR brachytherapy can be safely used as organ preserving modality of treatment for eyelid carcinoma.
ISSN:2234-1900
2234-3156
2234-3164
DOI:10.3857/roj.2023.00682